Table 3.

Adjusted HR of OS associated with different comorbidities on cDDD levels.

	28-167 cDDD				≥168 cDDD
Variables	HR	95% CI		P value	HR	95% CI		P value
Main model a	0.76	0.68	0.84	<.0001	0.48	0.41	0.57	<.0001
Additional covariatesb
Main model+ diabetes mellitus	0.75	0.68	0.84	<.0001	0.48	0.41	0.56	<.0001
Main model+ hypertension	0.76	0.68	0.84	<.0001	0.48	0.41	0.56	<.0001
Main model+ alcoholism	0.76	0.68	0.84	<.0001	0.48	0.41	0.57	<.0001
Main model+ smoking-related disorder	0.76	0.68	0.84	<.0001	0.48	0.41	0.56	<.0001
Main model+ chronic renal failure	0.76	0.68	0.84	<.0001	0.48	0.41	0.57	<.0001
Main model+ liver cirrhosis	0.76	0.68	0.84	<.0001	0.48	0.41	0.57	<.0001
Main model+ chemotherapy regimen	0.75	0.68	0.83	<.0001	0.48	0.41	0.57	<.0001
Subgroup effects
Sex
Male	0.78	0.68	0.89	.0002	0.51	0.41	0.62	<.0001
Female	0.73	0.61	0.86	.0002	0.45	0.35	0.58	<.0001
Age at surgery
18∼64 -year-old	0.81	0.70	0.94	.0057	0.47	0.37	0.59	<.0001
> 65-year-old	0.71	0.62	0.82	<.0001	0.50	0.40	0.62	<.0001

cDDD = cumulative defined daily dose, CI = confidence interval, HR = hazard ratio, MAOI = monoamine oxidase inhibitor, NDRI = norepinephrine-dopamine reuptake inhibitor, OS = overall survival, SARI = serotonin antagonist and reuptake inhibitor.

^∗a: Adjusted for all covariates (all kinds of ATD, sex age, urbanization, income).

^∗b: Other: combined SARI, NDRI, Mirtazapine, MAOI.